With the accelerated approval of erdafitinib for FGFR‐altered urothelial carcinoma in April 2019 and pemigatinib for cholangiocarcinoma with FGFR2 fusion or other rearrangements in April 2020,6, 7 the FGF‐FGFR signalling pathway has received more attention. This evidence concerns the gene FGFR2 and cholangiocarcinoma.